Aerovate Therapeutics plans to lay off nearly all its employees two weeks after its lead asset flunked a mid-stage trial.
The company disclosed the workforce …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.